文 献1）Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004; 127: 1075-84.2）Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, et al. Adenosine A2A receptors measured with 11C-TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011; 6(2): e17338.3）Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011; 76: 1811-6.4）Chen W, Wang H, Wei H, Gu S, Wei H. Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis. J Neurol Sci 2013; 324: 21-8.5）Tao Y, Liang G. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials. Cell Biochem Biophys 2015; 71: 57-62.6）Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. The effect of istradefylline for Parkinson's disease: A meta-analysis. Sci Rep 2017; 7: 18018.7）Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET. Neuropharmacology 2018; 143: 106-12.8）Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-8.9）Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 2002; 22: 1440-52.パーキンソン病におけるアデノシンA2A受容体の病態解析10）Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006; 55: 515-24.11）Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003; 61: S97-100.12）Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009; 330: 294-303.13）Neustadt BR, Liu H, Hao J, Greenlee WJ, Stamford AW, Foster C, et al. Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 2009; 19: 967-71.14）Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001; 24: 31-55.15）Zhou X, Boellaard R, Ishiwata K, Sakata M, Dierckx R, de Jong JR, et al. In Vivo Evaluation of 11C-Preladenant for PET Imaging of Adenosine A2A Receptors in the Conscious Monkey. J Nucl Med 2017; 58: 762-7.16）Zhou X, Khanapur S, de Jong JR, Willemsen AT, Dierckx RA, Elsinga PH, et al. In vivo evaluation of 11C-preladenant positron emission tomography for quantification of adenosine A2A receptors in the rat brain. J Cereb Blood Flow Metab 2017; 37: 577-89.23
元のページ ../index.html#37